{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:23Z","timestamp":1791994583776,"version":"4.4.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1-AI144288"],"award-info":[{"award-number":["UM1-AI144288"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01-AR068288"],"award-info":[{"award-number":["R01-AR068288"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jid.2021.04.040","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T02:42:11Z","timestamp":1635475331000},"page":"907-914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"PB","title":["Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-0491","authenticated-orcid":false,"given":"Christoph T.","family":"Ellebrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0722-6881","authenticated-orcid":false,"given":"Damian","family":"Maseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9389-7918","authenticated-orcid":false,"given":"Aimee S.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.04.040_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A\u00a0randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2133.1999.02752.x","article-title":"Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus","volume":"140","author":"Amagai","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib4","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.4049\/jimmunol.137.9.2835","article-title":"Defining the role of complement in experimental pemphigus vulgaris in mice","volume":"137","author":"Anhalt","year":"1986","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib5","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1038\/s41598-019-40203-7","article-title":"B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid [published correction appears in Sci Rep 2019;9:18991","volume":"9","author":"Berkani","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2021.04.040_bib6","doi-asserted-by":"crossref","first-page":"12855","DOI":"10.1073\/pnas.0602973103","article-title":"p38MAPK inhibition prevents disease in pemphigus vulgaris mice","volume":"103","author":"Berkowitz","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2021.04.040_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/08916930290016655","article-title":"Production of non-pathogenic human monoclonal antibodies to desmoglein 3 from pemphigus vulgaris patient","volume":"35","author":"Bhol","year":"2002","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jid.2021.04.040_bib8","doi-asserted-by":"crossref","first-page":"591971","DOI":"10.3389\/fimmu.2020.591971","article-title":"Milestones in personalized medicine in pemphigus and pemphigoid","volume":"11","author":"Bieber","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG\u00a0immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.jid.2021.04.040_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","volume":"96","author":"Chakievska","year":"2019","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jid.2021.04.040_bib11","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1365-2133.2010.09696.x","article-title":"Immune response towards the amino-terminus of desmoglein 1 prevails across different activity stages in nonendemic pemphigus foliaceus","volume":"162","author":"Chan","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib107","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.celrep.2016.12.013","article-title":"Proteomic analysis of pemphigus autoantibodies indicates a larger, more diverse, and more dynamic repertoire than determined by B cell genetics","volume":"18","author":"Chen","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jid.2021.04.040_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.06.066","article-title":"Single-cell analysis suggests that ongoing affinity maturation drives the emergence of pemphigus vulgaris autoimmune disease","volume":"28","author":"Cho","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jid.2021.04.040_bib14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4049\/jimmunol.1600567","article-title":"Determinants of VH1-46 cross-reactivity to pemphigus vulgaris autoantigen desmoglein 3 and rotavirus antigen VP6","volume":"197","author":"Cho","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib15","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1038\/ncomms5167","article-title":"Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients","volume":"5","author":"Cho","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2021.04.040_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jdermsci.2017.07.012","article-title":"IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid","volume":"88","author":"Dainichi","year":"2017","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2021.04.040_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13023-016-0494-z","article-title":"Combined integrated protocol\/basket trial design for a first-in-human trial","volume":"11","author":"Derhaschnig","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2021.04.040_bib19","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1172\/JCI64413","article-title":"Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface","volume":"122","author":"Di Zenzo","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.04.040_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid","volume":"128","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3389\/fimmu.2019.01477","article-title":"Complement activation in autoimmune bullous dermatoses: a comprehensive review","volume":"10","author":"Edwards","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.18237","article-title":"A\u00a0new ex\u00a0vivo human oral mucosa model reveals that p38MAPK inhibition is not effective in preventing autoantibody-induced mucosal blistering in pemphigus","volume":"182","author":"Egu","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jid.2021.04.040_bib24","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.celrep.2018.07.093","article-title":"Autoreactive IgG and IgA B cells evolve through distinct subclass switch pathways in the autoimmune disease pemphigus vulgaris","volume":"24","author":"Ellebrecht","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jid.2021.04.040_bib25","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-2133.2012.11144.x","article-title":"Enrichment of total serum IgG4 in patients with pemphigus","volume":"167","author":"Funakoshi","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0923-1811(00)00158-4","article-title":"Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus","volume":"26","author":"Futei","year":"2001","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2021.04.040_bib27","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.04.040_bib28","author":"Goebeler"},{"key":"10.1016\/j.jid.2021.04.040_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1993.01680220061016","article-title":"Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid","volume":"129","author":"Guillaume","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib30","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/jid.2013.236","article-title":"Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients","volume":"133","author":"Hall","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib31","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years","volume":"135","author":"Hammers","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jid.2021.04.040_bib33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jid.2019.11.005","article-title":"Recent advances in understanding pemphigus and bullous pemphigoid","volume":"140","author":"Hammers","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jid.2021.04.040_bib35","first-page":"1478","article-title":"Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid","volume":"18","author":"Holtsche","year":"2020","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.jid.2021.04.040_bib37","series-title":"Immune Pharmaceuticals presents updated positive results from Phase 2 trial of bertilimumab in bullous pemphigoid","year":"2018"},{"key":"10.1016\/j.jid.2021.04.040_bib38","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/sj.jid.5701132","article-title":"Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies","volume":"128","author":"Ishii","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib40","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.04.040_bib41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2013.02.011","article-title":"A\u00a0higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris","volume":"70","author":"Kamiya","year":"2013","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2021.04.040_bib42","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3389\/fimmu.2018.00488","article-title":"Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2","volume":"9","author":"Karsten","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib43","doi-asserted-by":"crossref","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2021.04.040_bib44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jid.2017.08.030","article-title":"The anti-C1s antibody TNT003 prevents complement activation in the skin induced by bullous pemphigoid autoantibodies","volume":"138","author":"Kasprick","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib45","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/sj.jid.5700450","article-title":"Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation","volume":"126","author":"Kawasaki","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib46","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib47","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jdcr.2015.07.014","article-title":"Bullous pemphigoid during ustekinumab therapy","volume":"1","author":"Le Guern","year":"2015","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2021.04.040_bib48","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"issue":"Suppl. 1","key":"10.1016\/j.jid.2021.04.040_bib49","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2021.04.040_bib50","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.04.040_bib51","series-title":"Pemphigus and pemphigoid","author":"Lever","year":"1965"},{"key":"10.1016\/j.jid.2021.04.040_bib52","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.04.040_bib53","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.1000667","article-title":"Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model","volume":"185","author":"Li","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2019.04.020","article-title":"Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a \"hit-and-run\" mechanism","volume":"144","author":"Lin","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1172\/JCI3693","article-title":"A\u00a0critical role for neutrophil elastase in experimental bullous pemphigoid","volume":"105","author":"Liu","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.04.040_bib56","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1084\/jem.188.3.475","article-title":"Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid","volume":"188","author":"Liu","year":"1998","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2021.04.040_bib57","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1111\/jdv.14002","article-title":"A\u00a0successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis","volume":"31","author":"Loget","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.04.040_bib58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdcr.2020.01.002","article-title":"Increasing evidence for omalizumab in the treatment of bullous pemphigoid","volume":"6","author":"Lonowski","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2021.04.040_bib59","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaci.2012.03.022","article-title":"Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus","volume":"130","author":"Lunardon","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92253","article-title":"Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes","volume":"2","author":"Mao","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2021.04.040_bib61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/jid.2013.224","article-title":"MAPKAP kinase 2 (MK2)-dependent and -independent models of blister formation in pemphigus vulgaris","volume":"134","author":"Mao","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ejhpharm-2018-001849","article-title":"Bullous pemphigoid induced by ustekinumab: a case report","volume":"28","author":"Marin","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.jid.2021.04.040_bib63","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/clin.1997.4408","article-title":"Mechanisms of acantholysis in pemphigus vulgaris: role of IgG valence","volume":"85","author":"Mascar\u00f3","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jid.2021.04.040_bib64","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.04.040_bib65","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.3389\/fimmu.2019.02331","article-title":"The intersection of IgE autoantibodies and eosinophilia in the pathogenesis of bullous pemphigoid","volume":"10","author":"Messingham","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib66","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib67","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1097\/TP.0000000000001804","article-title":"Blockade of HLA antibody-triggered classical complement activation in sera from subjects dosed with the anti-C1s monoclonal antibody TNT009-results from a randomized first-in-human phase 1 trial","volume":"101","author":"M\u00fchlbacher","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jid.2021.04.040_bib68","author":"Murrell"},{"key":"10.1016\/j.jid.2021.04.040_bib69","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/1346-8138.12943","article-title":"Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab","volume":"42","author":"Nakayama","year":"2015","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib70","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1074\/jbc.M309000200","article-title":"Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes","volume":"279","author":"Nguyen","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2021.04.040_bib71","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.4049\/jimmunol.1800998","article-title":"C1s inhibition by\u00a0BIVV009 (Sutimlimab) prevents complement-enhanced activation of autoimmune human B cells in\u00a0vitro","volume":"202","author":"Nikitin","year":"2019","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib72","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/jid.2011.448","article-title":"Epitope spreading is rarely found in pemphigus vulgaris by large-scale longitudinal study using desmoglein 2-based swapped molecules","volume":"132","author":"Ohyama","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib73","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1172\/JCI24185","article-title":"Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display","volume":"115","author":"Payne","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.04.040_bib74","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients","volume":"81","author":"Polansky","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib75","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/jid.2009.184","article-title":"Antigen selection of anti-DSG1 autoantibodies during and before the onset of endemic pemphigus foliaceus","volume":"129","author":"Qian","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib76","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.4049\/jimmunol.1200842","article-title":"Cutting Edge: Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen","volume":"189","author":"Qian","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib77","series-title":"South San Francisco, CA: Genentech","year":"2020"},{"key":"10.1016\/j.jid.2021.04.040_bib78","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1172\/JCI114426","article-title":"Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb\/c mice","volume":"85","author":"Rock","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.04.040_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050696","article-title":"Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation","volume":"7","author":"Saito","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2021.04.040_bib80","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3389\/fimmu.2018.00692","article-title":"Autoantibody signaling in pemphigus vulgaris: development of an integrated model","volume":"9","author":"Sajda","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib81","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1600-0625.2010.01069.x","article-title":"Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients","volume":"19","author":"Schmidt","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.04.040_bib83","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/all.13950","article-title":"Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study","volume":"75","author":"Simon","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jid.2021.04.040_bib84","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jid.2017.06.022","article-title":"Mechanisms causing loss of keratinocyte cohesion in pemphigus","volume":"138","author":"Spindler","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/15419061.2013.877000","article-title":"Desmosomal cadherins and signaling: lessons from autoimmune disease","volume":"21","author":"Spindler","year":"2014","journal-title":"Cell Commun Adhes"},{"key":"10.1016\/j.jid.2021.04.040_bib86","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1172\/JCI114266","article-title":"Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them","volume":"84","author":"Sugi","year":"1989","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.04.040_bib87","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0190-9622(90)70004-2","article-title":"Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies","volume":"22","author":"Tan-Lim","year":"1990","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib88","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1046\/j.0022-202x.2001.01505.x","article-title":"Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells","volume":"117","author":"Teraki","year":"2001","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib89","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaad.2019.11.023","article-title":"Clinical outcome and safety of rituximab therapy for pemphigoid diseases","volume":"82","author":"Tovanabutra","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib90","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1078-0432.CCR-11-1429","article-title":"Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma","volume":"18","author":"Tsai","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2021.04.040_bib91","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.4049\/jimmunol.170.4.2170","article-title":"Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3","volume":"170","author":"Tsunoda","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib92","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.04.040_bib93","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2353\/ajpath.2010.090744","article-title":"Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen","volume":"176","author":"Wang","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jid.2021.04.040_bib94","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaad.2020.02.020","article-title":"Comparison of C3d immunohistochemical staining to enzyme-linked immunosorbent assay and immunofluorescence for diagnosis of bullous pemphigoid","volume":"83","author":"Wang","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib95","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2021.04.040_bib108","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2021.04.040_bib96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2340\/00015555-2473","article-title":"The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use?","volume":"97","author":"Wijayanti","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2021.04.040_bib97","doi-asserted-by":"crossref","first-page":"11935","DOI":"10.1073\/pnas.92.25.11935","article-title":"Structural basis for major histocompatibility complex (MHC)- linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self- peptides in pemphigus vulgaris","volume":"92","author":"Wucherpfennig","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl.7","key":"10.1016\/j.jid.2021.04.040_bib98","first-page":"S7","article-title":"Pathogenic pemphigus foliaceus (PF) and vulgaris (PV) antibodies share a consensus amino acid motif in their CDR3 regions","volume":"128","author":"Yamagami","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib99","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.4049\/jimmunol.0901691","article-title":"Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus","volume":"183","author":"Yamagami","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib100","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.clim.2006.03.006","article-title":"Pathogenic human monoclonal antibody against desmoglein 3","volume":"120","author":"Yeh","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jid.2021.04.040_bib101","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jdermsci.2016.12.010","article-title":"Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering","volume":"85","author":"Yoshida","year":"2017","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2021.04.040_bib102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdermsci.2005.11.002","article-title":"Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid","volume":"41","author":"Yoshida","year":"2006","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2021.04.040_bib103","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.07.717","article-title":"Autoreactive B cell differentiation in diffuse ectopic lymphoid-like structures of inflamed pemphigus lesions","volume":"140","author":"Zhou","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1523-1747.ep12338088","article-title":"A\u00a0highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid","volume":"109","author":"Zillikens","year":"1997","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.040_bib106","article-title":"Disease remission during a short-term treatment phase II study of nomacopan in mild-to-moderate bullous pemphigoid - with final plan for phase III trial","author":"Nunn","year":"2021","journal-title":"Poster presented at the American Academy of Dermatology Virtual Meeting Experience"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21022211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21022211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:48:08Z","timestamp":1762206488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21022211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0022202X21022211"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.04.040","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.04.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}